左归丸联合丁苯酞佐治帕金森病轻度认知障碍疗效评价

Efficacy Evaluation of Zuogui Pills Combined with Butylphthalide in the Adjuvant Treatment of Mild Cognitive Impairment in Parkinson′s Disease

目的探讨左归丸联合丁苯酞佐治帕金森病轻度认知障碍的临床疗效。方法选取医院2023年1月至3月收治的帕金森病轻度认知障碍患者80例,按随机数字表法分为观察组和对照组,各40例。两组患者均予常规抗帕金森病西药治疗,并予丁苯酞软胶囊口服,观察组患者加服左归丸。两组均连续治疗8周。结果观察组总有效率为90.00%,显著高于对照组的70.00%(P<0.05)。治疗后,观察组患者的腰膝酸软、胁肋疼痛、头晕头痛中医证候积分均显著低于对照组(P<0.05);观察组患者的沉默信息调节因子1(SIRT1)蛋白表达水平显著高于对照组,核因子κB(NF-κB)蛋白表达水平显著低于对照组(P<0.05);观察组患者的蒙特利尔认知评估量表(MoCA)、简易精神状态量表(MMSE)及日常生活活动能力(ADL)量表评分均显著高于对照组(P<0.05);观察组患者的统一帕金森病评定量表(UPDRS)评分显著低于对照组(P<0.05)。观察组与对照组不良反应发生率相当(5.00%比2.50%,P>0.05)。结论常规抗帕金森病治疗基础上佐以左归丸联合丁苯酞,可降低帕金森病轻度认知障碍患者的中医证候积分,改善SIRT1及NF-κB蛋白表达水平,提升认知功能及日常生活能力。

Objective To investigate the clinical efficacy of Zuogui Pills combined with butylphthalide in the adjuvant treatment of mild cognitive impairment in Parkinson's disease.Methods Eighty patients with mild cognitive impairment in Parkinson's disease admitted to the hospital from January to March 2023 were selected and divided into the observation group and the control group by the random number table method,with 40 cases in each group.The patients in the two groups were given conventional western medicines for Parkinson's disease and Butylphthalide Soft Capsules orally,on this basis,the patients in the observation group were given Zuogui Pills.Both groups were treated continuously for eight weeks.Results The total effective rate in the observation group was 90.00%,which was significantly higher than 70.00%in the control group(P<0.05).After treatment,the scores of traditional Chinese medicine(TCM)syndromes including waist,knee soreness,rib pain,dizziness and headache in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the expression level of silent information regulator 1(SIRT1)protein in the observation group was significantly higher than that in the control group,and the expression level of nuclear factorsκB(NF-κB)protein was significantly lower than that in the control group(P<0.05).After treatment,the Montreal Cognitive Assessment(MoCA),Mini-Mental State Examination(MMSE)and Activity of Daily Living(ADL)scores in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the Unified Parkinson's Disease Rating Scale(UPDRS)score in the observation group was significantly lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was similar to that in the control group(5.00%vs.2.50%,P>0.05).Conclusion On the basis of conventional treatment,Zuogui Pills combined with butylphthalide in the adjuvant treatment of mild cognitive impairment in Parkinson's disease can decrease patients'TCM syndrome score,improve the expression levels of SIRT1,NF-κB proteins,enhance the cognitive function and activity ability of daily living.